Abstract: The present disclosure belongs to the field of pharmaceuticals. Disclosed is a use of bulleyaconitine A in treating pruritus or a secondary lesion thereof, especially pruritus induced by histamine and/or chloroquine.

Abstract: Disclosed in the present invention are a bulleyaconitine D crystal and a preparation method therefor. FIG. 1 shows an X-ray powder diffraction spectrum of the crystal according to the present invention, the spectrum being measured with Cu—K alpha ray. The bulleyaconitine D crystal is prepared by an anti-solvent process with isopropanol, anisole, 1,4-dioxane or methylbenzene acting as a positive solvent and n-heptane as a negative solvent. The preparation process is simple, and the prepared crystal has a high purity. Upon characterization via XRD, DSC, TGA and 1HNMR, the crystal is determined as D crystal type. Stability test shows that the prepared bulleyaconitine crystal is well stable to light, damp and heat.

Abstract: Provided is a crystal form E of bulleyaconitine A and a preparation method for the crystal form E of bulleyaconitine A. An X-ray powder diffraction spectrum of the crystal form measured by Cu-K?-ray is as shown in FIG. 1. The crystal form E of bulleyaconitine A is prepared by adding a mixed solution of alcohol and water to bulleyaconitine A, stirring to obtain a suspended solid, and centrifugally collecting the solid. The alcohol is methanol, ethanol or n-butanol. The preparation process is simple, and the obtained crystal form has high purity and is characterized by XRD, DSC, TGA, and 1HNMR to be determined as the crystal form E. The obtained bulleyaconitine A crystal is an anhydrous crystal form, and stability test results show that the crystal has good light, humidity and heat stability.

Abstract: The present disclosure belongs to the field of pharmaceuticals. Disclosed is a use of bulleyaconitine A in treating pruritus or a secondary lesion thereof, especially pruritus induced by histamine and/or chloroquine.